Cargando…
Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
BACKGROUND AND OBJECTIVES: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183702/ https://www.ncbi.nlm.nih.gov/pubmed/21976923 http://dx.doi.org/10.4103/0974-7796.84954 |
_version_ | 1782213032723611648 |
---|---|
author | Alkhateeb, Sultan S. Neill, Mischel Bar-Moshe, Sas Rhijn, Bas Van Kakiashvili, David M. Fleshner, Neil Jewett, Michael Petein, Michel Schulman, Claude Hanna, Sally Bostrom, Peter J. Roumeguere, Thierry Shariat, Shahrokh F. Rorive, Sandrine Zlotta, Alexandre R. |
author_facet | Alkhateeb, Sultan S. Neill, Mischel Bar-Moshe, Sas Rhijn, Bas Van Kakiashvili, David M. Fleshner, Neil Jewett, Michael Petein, Michel Schulman, Claude Hanna, Sally Bostrom, Peter J. Roumeguere, Thierry Shariat, Shahrokh F. Rorive, Sandrine Zlotta, Alexandre R. |
author_sort | Alkhateeb, Sultan S. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) treated with intravesical Bacille Calmette-Guérin (BCG) therapy. MATERIALS AND METHODS: This study included 42 patients accrued prospectively presenting with intermediate- to high-risk NMIBC (high-grade T1 tumors or multiple rapidly recurrent tumors refractory to intravesical chemotherapy) treated with transurethral resection (TUR) and BCG. TUR samples were analyzed for the molecular markers p53, p21 waf1/cip, Bcl-2, CyclinD1, and metallothionein 9 (MMP9) using immunohistochemistry. Frequency of positivity, measured as a percentage, was assessed alone or in combination with EORTC risk calculator, for interaction with outcome in terms of recurrence and progression using univariate analysis and Kaplan-Meier survival curves. RESULTS: Median follow-up was 88 months (mean, 99; range, 14-212 months). The overall recurrence rate was 61.9% and progression rate was 21.4%. In univariate analysis, CyclinD1 and EORTC risk groups were significantly associated with recurrence (P value 0.03 and 0.02, respectively), although none of the markers showed a correlation to progression. In combining EORTC risk groups to markers expression status, high-risk group associated with positive MMP9, Bcl-2, CyclinD1, or p21 was significantly correlated to tumor recurrence (log rank P values <0.001, 0.03, 0.02, and 0.006, respectively) and when associated with positive MMP9 or p21, it was significantly correlated to progression (log rank P values 0.01 and 0.04, respectively). CONCLUSION: Molecular markers have a long-term prognostic value when combined with EORTC scoring system and they may be used to improve the predictive accuracy of currently existing scoring system. Larger series are needed to confirm these findings. |
format | Online Article Text |
id | pubmed-3183702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-31837022011-10-05 Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin Alkhateeb, Sultan S. Neill, Mischel Bar-Moshe, Sas Rhijn, Bas Van Kakiashvili, David M. Fleshner, Neil Jewett, Michael Petein, Michel Schulman, Claude Hanna, Sally Bostrom, Peter J. Roumeguere, Thierry Shariat, Shahrokh F. Rorive, Sandrine Zlotta, Alexandre R. Urol Ann Original Article BACKGROUND AND OBJECTIVES: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) treated with intravesical Bacille Calmette-Guérin (BCG) therapy. MATERIALS AND METHODS: This study included 42 patients accrued prospectively presenting with intermediate- to high-risk NMIBC (high-grade T1 tumors or multiple rapidly recurrent tumors refractory to intravesical chemotherapy) treated with transurethral resection (TUR) and BCG. TUR samples were analyzed for the molecular markers p53, p21 waf1/cip, Bcl-2, CyclinD1, and metallothionein 9 (MMP9) using immunohistochemistry. Frequency of positivity, measured as a percentage, was assessed alone or in combination with EORTC risk calculator, for interaction with outcome in terms of recurrence and progression using univariate analysis and Kaplan-Meier survival curves. RESULTS: Median follow-up was 88 months (mean, 99; range, 14-212 months). The overall recurrence rate was 61.9% and progression rate was 21.4%. In univariate analysis, CyclinD1 and EORTC risk groups were significantly associated with recurrence (P value 0.03 and 0.02, respectively), although none of the markers showed a correlation to progression. In combining EORTC risk groups to markers expression status, high-risk group associated with positive MMP9, Bcl-2, CyclinD1, or p21 was significantly correlated to tumor recurrence (log rank P values <0.001, 0.03, 0.02, and 0.006, respectively) and when associated with positive MMP9 or p21, it was significantly correlated to progression (log rank P values 0.01 and 0.04, respectively). CONCLUSION: Molecular markers have a long-term prognostic value when combined with EORTC scoring system and they may be used to improve the predictive accuracy of currently existing scoring system. Larger series are needed to confirm these findings. Medknow Publications 2011 /pmc/articles/PMC3183702/ /pubmed/21976923 http://dx.doi.org/10.4103/0974-7796.84954 Text en © Urology Annals http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Alkhateeb, Sultan S. Neill, Mischel Bar-Moshe, Sas Rhijn, Bas Van Kakiashvili, David M. Fleshner, Neil Jewett, Michael Petein, Michel Schulman, Claude Hanna, Sally Bostrom, Peter J. Roumeguere, Thierry Shariat, Shahrokh F. Rorive, Sandrine Zlotta, Alexandre R. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin |
title | Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin |
title_full | Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin |
title_fullStr | Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin |
title_full_unstemmed | Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin |
title_short | Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin |
title_sort | long-term prognostic value of the combination of eortc risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical bacille calmette-guérin |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183702/ https://www.ncbi.nlm.nih.gov/pubmed/21976923 http://dx.doi.org/10.4103/0974-7796.84954 |
work_keys_str_mv | AT alkhateebsultans longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT neillmischel longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT barmoshesas longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT rhijnbasvan longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT kakiashvilidavidm longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT fleshnerneil longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT jewettmichael longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT peteinmichel longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT schulmanclaude longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT hannasally longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT bostrompeterj longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT roumeguerethierry longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT shariatshahrokhf longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT rorivesandrine longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin AT zlottaalexandrer longtermprognosticvalueofthecombinationofeortcriskgroupcalculatorandmolecularmarkersinnonmuscleinvasivebladdercancerpatientstreatedwithintravesicalbacillecalmetteguerin |